These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
6. Meropenem-Vaborbactam Activity against Carbapenem-Resistant Castanheira M; Doyle TB; Kantro V; Mendes RE; Shortridge D Antimicrob Agents Chemother; 2020 Jan; 64(2):. PubMed ID: 31712207 [TBL] [Abstract][Full Text] [Related]
7. Assessing the in vivo impact of novel β-lactamase inhibitors on the efficacy of their partner β-lactams against serine carbapenemase-producing Pseudomonas aeruginosa using human-simulated exposures. Ruiz VH; Gill CM; Nicolau DP J Antimicrob Chemother; 2024 Mar; 79(3):546-551. PubMed ID: 38217443 [TBL] [Abstract][Full Text] [Related]
8. Activity of Meropenem-Vaborbactam in Mouse Models of Infection Due to KPC-Producing Carbapenem-Resistant Enterobacteriaceae. Sabet M; Tarazi Z; Nolan T; Parkinson J; Rubio-Aparicio D; Lomovskaya O; Dudley MN; Griffith DC Antimicrob Agents Chemother; 2018 Jan; 62(1):. PubMed ID: 29109160 [TBL] [Abstract][Full Text] [Related]
9. Activity of meropenem/vaborbactam and comparators against Gram-negative isolates from Eastern and Western European patients hospitalized with pneumonia including ventilator-associated pneumonia (2014-19). Shortridge D; Carvalhaes C; Deshpande L; Castanheira M J Antimicrob Chemother; 2021 Sep; 76(10):2600-2605. PubMed ID: 34302173 [TBL] [Abstract][Full Text] [Related]
10. In vitro activity of meropenem/vaborbactam and characterisation of carbapenem resistance mechanisms among carbapenem-resistant Enterobacteriaceae from the 2015 meropenem/vaborbactam surveillance programme. Pfaller MA; Huband MD; Mendes RE; Flamm RK; Castanheira M Int J Antimicrob Agents; 2018 Aug; 52(2):144-150. PubMed ID: 29510189 [TBL] [Abstract][Full Text] [Related]
11. The paradoxical in vivo activity of β-lactams against metallo-β-lactamase-producing Enterobacterales is not restricted to carbapenems. Abdelraouf K; Reyes S; Nicolau DP J Antimicrob Chemother; 2021 Feb; 76(3):684-691. PubMed ID: 33179050 [TBL] [Abstract][Full Text] [Related]
12. Comparative in vivo activity of human-simulated plasma and epithelial lining fluid exposures of WCK 5222 (cefepime/zidebactam) against KPC- and OXA-48-like-producing Klebsiella pneumoniae in the neutropenic murine pneumonia model. Lasko MJ; Abdelraouf K; Nicolau DP J Antimicrob Chemother; 2021 Aug; 76(9):2310-2316. PubMed ID: 34096601 [TBL] [Abstract][Full Text] [Related]
13. Effect of the β-Lactamase Inhibitor Vaborbactam Combined with Meropenem against Serine Carbapenemase-Producing Enterobacteriaceae. Castanheira M; Rhomberg PR; Flamm RK; Jones RN Antimicrob Agents Chemother; 2016 Sep; 60(9):5454-8. PubMed ID: 27381386 [TBL] [Abstract][Full Text] [Related]
18. In vivo exposure-response relationship of meropenem against metallo-β-lactamase-harbouring Pseudomonas aeruginosa: an assessment using MICs from conventional and zinc-limited broth. Kois AK; Nicolau DP; Asempa TE J Antimicrob Chemother; 2022 Jun; 77(7):1938-1948. PubMed ID: 35488847 [TBL] [Abstract][Full Text] [Related]
19. Pharmacokinetic-Pharmacodynamic Target Attainment Analyses as Support for Meropenem-Vaborbactam Dosing Regimens and Susceptibility Breakpoints. Bhavnani SM; Trang M; Griffith DC; Lomovskaya O; Hammel JP; Loutit JS; Cammarata SK; Dudley MN; Ambrose PG; Rubino CM Antimicrob Agents Chemother; 2022 Dec; 66(12):e0213021. PubMed ID: 36374023 [TBL] [Abstract][Full Text] [Related]
20. Activity of Simulated Human Dosage Regimens of Meropenem and Vaborbactam against Carbapenem-Resistant Enterobacteriaceae in an Sabet M; Tarazi Z; Rubio-Aparicio D; Nolan TG; Parkinson J; Lomovskaya O; Dudley MN; Griffith DC Antimicrob Agents Chemother; 2018 Feb; 62(2):. PubMed ID: 29133570 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]